The Jackson Laboratory

Post on 26-Dec-2014

102 views 0 download

description

Presentation by Dr. Richard Longeras to members of the New Orleans bioscience community. Hosted by BioDistrict New Orleans on Tuesday March 29, 2011.

Transcript of The Jackson Laboratory

Presentation Prepared for

Richard Longeras, Ph.D. 03/29/11

richard.longeras@jax.org

About Jackson

richard.longeras@jax.org

How it all began…

“The mission of the Roscoe B. Jackson Memorial Laboratory is to eliminate the chief scourge of mankind -cancer.” -Clarence Cook Little

Clarence Cook Little

•  Experiments initiated to create the first inbred

mouse strain ~1907

•  Innovative and bold new insights into complex

traits and cancer biology

• Founded The Jackson Laboratory in 1929

richard.longeras@jax.org

The Jackson Laboratory then…

The Jackson Laboratory, 1929

Research Staff, 1930

richard.longeras@jax.org

Human Health Advances

Elizabeth Russell, PhD Pioneered the use of bone marrow transplants

George Snell, PhD & Nobel Prize Recipient Discoveries of immune system function formed the

foundation for tissue and organ transplantation

Leroy Stevens, PhD Laid the foundation for modern stem cell research

1940s

1950s

1960s

richard.longeras@jax.org

The Jackson Laboratory now… Basic Research, Genetic Resources, Preclinical Research Services, Education

Leading provider of genetically defined mice and services including pre-clinical research

World renown non-profit genetics research institute and international training center

Bar Harbor, ME

Sacramento, CA

richard.longeras@jax.org

The Jackson Laboratory: •  Research: Genetics and

biology of human disease with currently 39 Primary Investigators

•  Resources: JAX® Mice, JAX® Services, bioinformatics databases

•  Education: World-class courses, conferences, and training programs

richard.longeras@jax.org

The Opportunity

richard.longeras@jax.org

The Changing Drug Discovery Landscape

Increased Pharma/Academia Collaborations •  Pharma looking for low risk, to lower cost of failure

•  Requires extensive proof-of -concept to consider licensing

•  Robust patent protection needed for major therapeutic

development

Academia •  Focused on early discovery/model development

•  Generation of peer reviewed preclinical data

•  Use of patents to maximize utility of new developments

richard.longeras@jax.org

The Changing Drug Discovery Landscape

Increased NIH funding in translational research •  Transform basic discovery to clinical relevancy

•  Accelerate data translation from bench to the bedside

NIH embracing stem cell research •  Change in administration will lead to

increased funding opportunities

•  Process for translating stem cell therapy to

the clinic needs to be established

richard.longeras@jax.org

richard.longeras@jax.org

JAX® In Vivo Services

richard.longeras@jax.org

Why the Mouse: Proof of Concept The power of mouse genetics •  Almost every human gene has a mouse counterpart •  Spontaneous mutations in mice mimic many human diseases •  The mouse genome can be readily manipulated (transgenics, knock-outs, knock-ins, tissue specific & inducible

expression, reporter genes)

Mouse models of human disease •  100’s of models for common diseases (obesity, diabetes, atherosclerosis, cancer, hypertension, arthritis,

Alzheimer’s, neuromuscular, autoimmunity…) •  Humanized models emerging for many diseases •  Complete physiological disease characterization and in vivo

efficacy testing

richard.longeras@jax.org

How JAX® In Vivo Services can help: •  Provide seamless access to the worlds largest collection

of mouse models of human disease

•  Allows inventors to rapidly and confidentially; –  Confirm their findings in a independent laboratory –  Increase the scale of experiments to improve statistical

power of conclusions –  Make direct comparisons to other reference models –  Expand the utility of their discoveries (many of today’s

targets impact multiple therapeutic areas) –  Generate new discoveries

•  Provide timely data for patent filings

richard.longeras@jax.org

JAX Mice & Services: Resources for Discovery

Mouse Models • Over 5,000 strains of JAX® Mice

• Novel strain creation

• Pretreatment e.g. diet, chemical, surgical modification

Colony Management • IVF-based expansion

• Sperm Cryopreservation

• 79 years experience in maintaining genetically defined mice

Model Characterization • High throughput, non-invasive

phenotyping platforms.

• Gene Expression analysis

• Histopathology

Drug Efficacy Testing • Standard and emerging disease models

• Skilled in all commonly used dosing routes and procedures

• Backed by the scientific expertise of The Jackson Laboratory

richard.longeras@jax.org

JAX® In Vivo Services •  Experienced and long tenured technical staff

•  Flexible, highly customizable study design

•  Documented success in rapid implementation of new methods and protocols

•  Supported by the expertise of Jackson research scientists

richard.longeras@jax.org

Therapeutic Areas Investigated to Date Metabolic disorders •  Obesity •  Type 2 Diabetes •  Cardiovascular disease •  Phenylketonuria •  Glycogen Storage Disease

Neurodegenerative/Neuromuscular diseases •  Amyotrophic Lateral Sclerosis •  Ataxia telangiectasia •  Parkinsons’ disease* •  Duchenne Muscular Dystrophy

Oncology •  Xenograft (NCI-60 plus WSU-DLCL2 NHL cell line) •  Orthotopic transplant •  Spontaneous/genetic models •  Teratoma pluripotency •  Engraftment of human primary tumor samples*

Inflammation and autoimmune •  Asthma •  Arthritis •  EAE-Multiple Sclerosis •  Inflammatory Bowel Disease •  Graft vs Host Disease* •  Type 1 Diabetes

Skin disorders •  Psoriasis •  Contact Dermatitis •  Alopecia

Blood disorders •  Sickle Cell Anemia •  Thrombocytopenia •  Bleeding disorders

Regenerative medicine •  Wound healing •  Bone loss

7

*in validation

richard.longeras@jax.org

29 richard.longeras@jax.org

richard.longeras@jax.org

•  Dosing by all commonly used routes: –  IP, IV, SC, PO, IM, ID, HTV –  IV catheter –  Intrarectal –  Osmotic pump –  In food or water

•  Experienced with a wide range of agents –  Small molecules –  Peptides –  Antibodies –  siRNAs –  Embryonic stem cells

General Methods and Procedures

richard.longeras@jax.org

In Vivo Services: Supporting Services Histopathology:

The Jackson Laboratory UC Davis Comparative Pathology Lab

Blood chemistry: The Jackson Laboratory UC Davis Comparative Pathology Lab

Cytokines, adipokines, etc: Millipore

Immunocytochemistry: Premier Laboratory

Analytical Analysis: PharmOptima

RNA Analysis: The Jackson Laboratory

richard.longeras@jax.org

JAX® In Vivo Services

New Models and Services

richard.longeras@jax.org

Leading Model for Humanization: NSG Strain name: NOD.Cg-Prkdc scid Il2rgtm1Wjl/SzJ Common name: NOD scid gamma (NSG) Stock number: 005557

1

No B cells No T cells

Deficient in multiple cytokine signaling pathways

No complement 5 No NK cells

Reduced dendritic cell function

Webpage: http://jaxmice.jax.org/strain/005557.html

Online user discussion forum: http://community.jax.org/forums/5.aspx

Leading Model for Humanization: NSG

2

Features: •  Severe defects in both innate and adaptive immunity •  Develops functional human immune system following engraftment

Applications: •  Investigation of leukemic stem cells (Ishikawa F, et al. 2007. Nat Biotechnol) •  Preservation of primary human tumor structure (Simpson-Abelson MR, et al.

2008. J Immunol) •  Evaluation of potential anti-HIV therapies (Kumar P, et al. 2008. Cell) •  Identification of multipotent hematopoietic progenitors (Majeti R, et al. 2007.

Cell Stem Cell) •  Examination of tumorigenic cells in human melanoma (Quintana, et al. 2008.

Nature) •  Investigation of human mammary stem cells (Eirew, et al. 2008. Nat Medicine)

richard.longeras@jax.org

In Vivo Services for Therapeutic Stem Cells Model Application Status

Pluripotency Assay Establish pluripotent potential of new stem cell lines

Available

STZ Induction Type 1 diabetes

Pancreatic Islet Replacement

Available

MPTP Model of Parkinson’s

Cell replacement In Development

Stroke Cell replacement In Development

Spinal Cord Injury Cell replacement Planned

richard.longeras@jax.org

Working with us:

•  Projects developed and managed by Ph.D. Study Directors

•  Study initiation usually begins within 2 to 4 weeks

•  Data updates provided weekly or as requested

•  Final report is provided within 30 days of study completion, unless otherwise specified.

richard.longeras@jax.org

richard.longeras@jax.org

We discover the genetic basis for preventing, treating and curing human disease, and we enable research and education for the global biomedical community.